The hypothesis to be tested of this study is that treatment with fluticasone propionate leads
to an initial improvement in symptoms, quality of life and lungfunction and a reduction in
airways hyperresponsiveness. The continued decline of lungfunction in COPD may not be
influenced by longer lasting treatment. Addition of salmeterol will augment the initial
benefits of fluticasone without changing the longterm decline in lungfunction.
Phase:
Phase 4
Details
Lead Sponsor:
Leiden University Medical Center
Collaborators:
Academisch Ziekenhuis Groningen GlaxoSmithKline Netherlands Organisation for Scientific Research The Netherlands Asthma Foundation